<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26841937</article-id><article-id pub-id-type="pmc">4739389</article-id><article-id pub-id-type="publisher-id">1195</article-id><article-id pub-id-type="doi">10.1186/s13063-016-1195-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: &#x02018;Phase II/III weekly <italic>nab</italic>-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yardley</surname><given-names>Denise A.</given-names></name><address><email>dyardley@tnonc.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Brufsky</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Coleman</surname><given-names>Robert E.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Conte</surname><given-names>Pierfranco F.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Cortes</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Gl&#x000fc;ck</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Nabholtz</surname><given-names>Jean-Mark A.</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Shaughnessy</surname><given-names>Joyce</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>Robert M.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Renschler</surname><given-names>Markus F.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Barton</surname><given-names>Debora</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Harbeck</surname><given-names>Nadia</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><aff id="Aff1"><label/>Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN 37203 USA </aff><aff id="Aff2"><label/>University of Pittsburgh Medical Center, Pittsburgh, PA USA </aff><aff id="Aff3"><label/>Weston Park Hospital, Sheffield Cancer Research Center, Sheffield, England </aff><aff id="Aff4"><label/>Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, and Istituto Oncologico Veneto IRCCS, Padova, Italy </aff><aff id="Aff5"><label/>Vall d&#x02019;Hebron Institute of Oncology (VHIO), Barcelona, Spain </aff><aff id="Aff6"><label/>Celgene Corporation, Summit, NJ USA </aff><aff id="Aff7"><label/>Centre de Lutte Contre le Cancer d&#x02019;Auvergne, Clermont Ferrand, France </aff><aff id="Aff8"><label/>Texas Oncology-Baylor Charles A. Sammons Center; US Oncology, Dallas, TX USA </aff><aff id="Aff9"><label/>Breast Center, University of Munich, Munich, Germany </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>63</elocation-id><permissions><copyright-statement>&#x000a9; Yardley et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d30e69" ext-link-type="doi" xlink:href="10.1186/s13063-015-1101-7"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Unfortunately, the original version of this article [<xref ref-type="bibr" rid="CR1">1</xref>] contained a few formatting errors which have been corrected via an update. In the eighth paragraph of the background there was an error. The original read as, &#x0201c;A phase II study evaluating the combination of nab-paclitaxel plus carboplatin as 199 first-line treatment for mTNBC is currently under way [31].&#x0201d; But should have read as &#x0201c;A phase II study evaluated the combination of nab-paclitaxel plus carboplatin a first-line treatment for mTNBC [31].&#x0201d;</p></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1186/s13063-015-1101-7.</p></fn></fn-group><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yardley</surname><given-names>DA</given-names></name><name><surname>Brufsky</surname><given-names>A</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name><name><surname>Conte</surname><given-names>PF</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Gl&#x000fc;ck</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase II/III weekly <italic>nab</italic>-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2015</year><volume>16</volume><fpage>575</fpage><pub-id pub-id-type="doi">10.1186/s13063-015-1101-7</pub-id><pub-id pub-id-type="pmid">26673577</pub-id></element-citation></ref></ref-list></back></article>